Watch a 54-minute medical lecture from Dana-Farber Cancer Institute where Dr. Heather A. Parsons, MD, MPH, provides a comprehensive overview of biopsy methods in metastatic breast cancer treatment. Learn about the differences between tissue and liquid biopsies, their clinical applications, and testing procedures for ER, PR, and HER2 status. Explore key topics including microsatellite status, tumor fraction analysis, ESR1 testing timing and dynamics, and circulating tumor DNA (ctDNA) testing in various contexts including lobular cancer. Gain insights into current clinical trials, treatment considerations for brain metastases, and the future of ctDNA testing programs. Discover how these diagnostic tools are advancing personalized treatment approaches for metastatic breast cancer patients.
How Tissue and Liquid Biopsies Are Used in Metastatic Breast Cancer Treatment - 2022-2023
Dana-Farber Cancer Institute via YouTube
Overview
Syllabus
Intro
What is a metastatic biopsy
Challenges
Questions
How do we test ER PR HER2
When to do a liquid biopsy vs a tissue biopsy
Can you take old tissue biopsies and retest
Is there a reason why microsatellite status and tumor fraction might not be determined
Tell us what you mean by DNA being cleared
When is the best time to get an ESR1 test
ESR1 status is dynamic
Can ESR1 go away
Is Neurontin prescribed clinically
Are clinical trials underway
Can CT tests capture tumor material from brain metastases
Can CT tests capture tumor material from cerebrospinal fluid
Are plans to do a similar type of trial in patients with metastatic triple negative breast cancer
Is it more or less important to get a CTDNA test in the setting of lobular cancer
Can you tell us more about the CTDNA program
Taught by
Dana-Farber Cancer Institute
